Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1

Vaccine

Volumn 29, Issue 47, 2011, Pages 8542-8548

  Wang, Ji ^a,b,c   Xu, Liling ^a,b,c   Tong, Pei ^a,b,c   Chen, Ying Hua ^a,b,c  

^a TSINGHUA UNIVERSITY   (China)

^b Beijing Key Laboratory for Protein Therapeutics   (China)

^c MOE Laboratory of Protein Science   (China)

Author keywords

2F5 epitope; HIV 1; Mucosal antibody; Transcytosis

Indexed keywords

EPITOPE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; TRANSCYTOSIS; VIRUS NEUTRALIZATION;

ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; EPITOPES; FEMALE; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; TANDEM REPEAT SEQUENCES; TRANSCYTOSIS; VACCINATION;

EID: 82455210416     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.032     Document Type: Article

References (47)

1. Haynes B.F., Shattock R.J. Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol 2008, 122(July (1)):3-9. quiz 10-1.
2. Pope M., Haase A.T. Transmission acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003, 9(July (7)):847-852.
3. Chun T.W., Engel D., Berrey M.M., Shea T., Corey L., Fauci A.S. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998, 95(July (15)):8869-8873.
4. Johnston M.I., Fauci A.S. An HIV vaccine-evolving concepts. N Engl J Med 2007, 356(May (20)):2073-2081.
5. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997, 3(January (1)):42-47.
6. Neutra M.R., Frey A., Kraehenbuhl J.P. Epithelial M cells: gateways for mucosal infection and immunization. Cell 1996, 86(August (3)):345-348.
7. Belyakov I.M., Berzofsky J.A. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 2004, 20(March (3)):247-253.
8. Bomsel M., David V. Mucosal gatekeepers: selecting HIV viruses for early infection. Nat Med 2002, 8(February (2)):114-116.
9. Yahi N., Baghdiguian S., Moreau H., Fantini J. Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT29 cells. J Virol 1992, 66(August (8)):4848-4854.
10. Bomsel M., Heyman M., Hocini H., Lagaye S., Belec L., Dupont C., et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998, 9(August (2)):277-287.
11. Hocini H., Belec L., Iscaki S., Garin B., Pillot J., Becquart P., et al. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retroviruses 1997, 13(September (14)):1179-1185.
12. Alfsen A., Iniguez P., Bouguyon E., Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001, 166(May (10)):6257-6265.
13. Devito C., Broliden K., Kaul R., Svensson L., Johansen K., Kiama P., et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000, 165(November (9)):5170-5176.
14. Shen R., Drelichman E.R., Bimczok D., Ochsenbauer C., Kappes J.C., Cannon J.A., et al. GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J Immunol 2010, 184(April (7)):3648-3655.
15. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6(February (2)):207-210.
16. Matoba N., Magerus A., Geyer B.C., Zhang Y.F., Muralidharan M., Alfsen A., et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci USA 2004, 101(September (37)):13584-13589.
17. Matoba N., Geyer B.C., Kilbourne J., Alfsen A., Bomsel M., Mor T.S. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR649-684, a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 2006, 24(June (23)):5047-5055.
18. Matoba N., Griffin T.A., Mittman M., Doran J.D., Alfsen A., Montefiori D.C., et al. Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. Curr HIV Res 2008, 6(May (3)):218-229.
19. Decroix N., Quan C.P., Pamonsinlapatham P., Bouvet J.P. Mucosal immunity induced by intramuscular administration of free peptides in-line with PADRE: IgA antibodies to the ELDKWA epitope of HIV gp41. Scand J Immunol 2002, 56(July (1)):59-65.
20. Jain S., Patrick A.J., Rosenthal K.L. Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen. Vaccine 2010, 28(October (43)):7070-7080.
21. Liu Z., Xiao Y., Chen Y.H. Epitope-vaccine strategy against HIV-1: today and tomorrow. Immunobiology 2003, 208(4):423-428.
22. Zhang G., Lu H., Lu Y., Jiang S., Chen Y.H. Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies. Immunobiology 2005, 210(9):639-645.
23. Zhang G., Chen Y.H. ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation. Immunobiology 2003, 207(4):259-264.
24. Qi Y., Liu L.C., Zhang B.Q., Shen Z., Wang J., Chen Y.H. Characterization of antibody responses against a neutralizing epitope on the glycoprotein E2 of classical swine fever virus. Arch Virol 2008, 153(8):1593-1598.
25. Heyndrickx L., Vermoesen T., Vereecken K., Kurth J., Coppens S., Aerts L., et al. Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays. J Virol Methods 2008, 148(March (1-2)):166-173.
26. Wang J., Tong P., Lu L., Zhou L., Xu L., Jiang S., et al. HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. PLoS ONE 2011, 6(3):e18233.
27. Chen X., Lu L., Qi Z., Lu H., Wang J., Yu X., et al. Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. J Biol Chem 2010, 285(August (33)):25506-25515.
28. Zhang R.G., Westbrook M.L., Westbrook E.M., Scott D.L., Otwinowski Z., Maulik P.R., et al. The 2.4Å crystal structure of cholera toxin B subunit pentamer: choleragenoid. J Mol Biol 1995, 251(August (4)):550-562.
29. Merritt E.A., Zhang Z., Pickens J.C., Ahn M., Hol W.G., Fan E. Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin. J Am Chem Soc 2002, 124(July (30)):8818-8824.
30. Ruprecht C.R., Krarup A., Reynell L., Mann A.M., Brandenberg O.F., Berlinger L., et al. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med 2011, 208(March (3)):439-454.
31. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(December (23)):2209-2220.
32. McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33(October (4)):542-554.
33. Bomsel M., Tudor D., Drillet A.S., Alfsen A., Ganor Y., Roger M.G., et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34(February (2)):269-280.
34. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67(November (11)):6642-6647.
35. Mehandru S., Wrin T., Galovich J., Stiegler G., Vcelar B., Hurley A., et al. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol 2004, 78(December (24)):14039-14042.
36. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004, 78(December (23)):13232-13252.
37. Chen Y.H., Xiao Y., Yu T., Dierich M.P. Epitope vaccine: a new strategy against HIV-1. Immunol Today 1999, 20(December (12)):588-589.
38. Xiao Y., Liao M., Lu Y., Dierich M.P., Chen Y.H. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1. Immunobiology 2000, 201(January (3-4)):323-331.
39. Xiao Y., Zhao Y., Lu Y., Chen Y.H. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody. Immunol Invest 2000, 29(February (1)):41-50.
40. Liu W., Peng Z., Liu Z., Lu Y., Ding J., Chen Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23(December (3)):366-371.
41. Qi Y., Zhang B.Q., Shen Z., Chen Y.H. Candidate vaccine focused on a classical swine fever virus epitope induced antibodies with neutralizing activity. Viral Immunol 2009, 22(June (3)):205-213.
42. Liu W.L., Chen Y.H. High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur J Immunol 2005, 35(February (2)):505-514.
43. Shang H., Han X., Shi X., Zuo T., Goldin M., Chen D., et al. Genetic and neutralization sensitivity of diverse HIV-1 ENV clones from chronically infected patients in China. J Biol Chem 2011, 286(April (16)):14531-14541.
44. Zhang Y., Lu L., Ba L., Liu L., Yang L., Jia M., et al. Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med 2006, 3(November (11)):e443.
45. Neurath A.R., Strick N., Jiang S.B., Li Y.Y., Debnath A.K. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of dead-end gp41 six-helix bundles. BMC Infect Dis 2002, 2(April):41.
46. Chomont N., Hocini H., Gody J.C., Bouhlal H., Becquart P., Krief-Bouillet C., et al. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Virology 2008, 370(January (2)):246-254.
47. VanCott T.C., Kaminski R.W., Mascola J.R., Kalyanaraman V.S., Wassef N.M., Alving C.R., et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 1998, 160(February (4)):2000-2012.